INO shares are up +7.63% intraday, trading near $1.27 versus a $1.18 prior close, during regular market hours. The primary catalyst is a newly announced collaboration with Akeso, Dana-Farber Cancer Institute, and Mass General Brigham to evaluate Akeso's cadonilimab combined with Inovio's DNA medicine INO-5412 in glioblastoma.
ASST is up roughly +11.20% during regular market hours, rising from Friday's $18.22 close to about $20.26. The rally is tied to its Bitcoin-treasury strategy, with Strive announcing the purchase of an additional 1,110 BTC (~$81.5M).
Strive (ASST) shares climbed roughly 76% over the trailing 30 days, from about $11.49 to above $20, as Bitcoin staged a sharp late-August breakout. The rally was amplified by aggressive Bitcoin accumulation, with the company's treasury reaching approximately 21,356 BTC after a $81.5 million purchase.
Northwest Biotherapeutics (NWBO) trades near $0.18 per share on the OTCQB, within a 52-week range of roughly $0.14 to $0.37, after a modest, single-digit move over the trailing 30 days. The company's core asset is DCVax-L, a personalized dendritic-cell therapy that completed a 331-patient Phase III trial in glioblastoma (GBM) and was published in JAMA Oncology.
VOO is trading down -0.16% to roughly $702.56 during Monday's regular session, versus Friday's close of $703.71. The move came as the S&P 500 opened lower, weighed by renewed caution over US economic sanctions against Iran and lingering Middle East uncertainty.
INTC fell -4.27% to $86.22 during regular market hours, down from the prior session close of $90.07. Primary catalyst: Intel announced a $15 billion common stock offering, triggering dilution concerns among shareholders.
AMAT fell -3.27% to about $476.22 during regular trading hours, deepening its recent pullback. The decline was part of a broad semiconductor selloff, with the Philadelphia Semiconductor Index sliding roughly -4% and peers like Micron, Lam Research and TSMC lower.
MU is down -6.62% to $902.80 during Monday's regular session, extending a premarket slide of roughly -3% to -4%. Primary catalyst: Samsung shares plunged about -9% after its record shareholder-return plan fell short of expectations, dragging global memory-chip stocks lower.
Applied Materials (NASDAQ: AMAT ) currently trades near $539, roughly 48% below the $800 threshold, after pulling back from its 52-week high of $739.67. The strongest bullish factors include surging AI-driven wafer fab equipment (WFE) demand, management's raised calendar 2026 semiconductor equipment growth outlook above 30%, and Applied Materials' dominant position in deposition, etch, and advanced packaging tools.
AZTA fell -11.5% during regular trading, sliding from Friday's $37.40 close to about $33.10. The selloff was triggered by the abrupt resignation of CEO John Marotta, announced Monday morning.
RGNX is down roughly -23.6% to $8.19 from a prior close of $10.72, with the selloff beginning in premarket trading and extending into Monday's regular session. The move was triggered by the FDA placing a clinical hold on RGX-121, the company's Hunter syndrome (MPS II) gene therapy, after asymptomatic spine MRI findings in five CAMPSIITE study participants.
FCEL is down -10.13% to $17.56 during regular Monday trading, sliding from last Friday's $19.54 close. The move reflects a sector-wide rotation out of high-beta, cash-burning fuel-cell and hydrogen names, with no company-specific announcement today.
SNDK fell -9.92% to about $1,438, extending a decline that began in premarket trading. Primary catalyst: strong fiscal Q4 results (revenue +372% YoY) were overshadowed by softer FQ1 revenue guidance of $10.3–10.8B, missing top-end consensus and stoking fears of slowing NAND price growth.
AXTI is trading down roughly -11.68% during the regular session, near $62.48 versus Friday's $70.74 close, after sliding pre-market. The primary catalyst is a broad optical-connectivity selloff driven by co-packaged optics (CPO) concerns.
AAOI is trading down -17.54% to $102.93 during Monday's regular session, extending a premarket slide of roughly -12% after a Friday after-hours filing. The primary catalyst is a newly disclosed $600 million at-the-market equity offering through Raymond James and Needham, its third ATM raise this year, sparking dilution concerns.
OABI rose +0.70% (+$0.03) to close at $4.33 during Friday's regular trading session, extending a multi-day advance. The move continues momentum from the Aug. 17 Eli Lilly collaboration and license agreement, which offers up to $370M in milestone payments plus tiered royalties.
Silence Therapeutics shares rose roughly 20% over the 30-day period, driven by positive clinical data and a major capital raise. The biggest catalyst was positive Phase 2 topline results for divesiran in polycythemia vera, which sent the stock up about 29% in a single session to a 52-week high.
Achieve Life Sciences (ACHV) rose roughly 31% over the last 30 days, from a closing price near $6.10 in late July to about $7.99 by late August. The gain extended a broader advance of approximately 70% over the past three months, driven by progress on the company's cytisinicline regulatory pathway.
PaySign (PAYS) shares climbed roughly 62% over the 30-day period, rising from an adjusted close of $8.69 to about $14.09. The move was driven primarily by better-than-expected second-quarter 2026 results reported on August 5, 2026, including a 48% year-over-year revenue increase and a raised full-year outlook.
VREX closed up +0.11% (+$0.02) at $18.51 in Friday's regular session, the latest completed session before Monday's open. The gain reflects consolidation, with shares pinned just below the $18.90 per-share all-cash Teledyne Technologies acquisition offer (~$1.1 billion, announced Aug. 10).